Last reviewed · How we verify
xin te mie
Xin te mie is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
Xin te mie is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes, Hypertension.
At a glance
| Generic name | xin te mie |
|---|---|
| Also known as | te mie jun, xin ke jun |
| Sponsor | Xiangbei Welman Pharmaceutical Co., Ltd |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
By inhibiting SGLT2, xin te mie reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is associated with several therapeutic benefits, including improved glycemic control and weight loss.
Approved indications
- Type 2 diabetes
- Hypertension
Common side effects
- Increased risk of diabetic ketoacidosis
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Increased risk of hypotension
- Increased risk of acute kidney injury
Key clinical trials
- Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection (PHASE4)
- Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |